CNSP
NASDAQCNS Pharmaceuticals Inc.
Price$4.44+0.98 (+28.32%)
2026-03-102026-06-11
News · 26 weeks31+17%
2025-12-142026-06-07
Mix1490d
- SEC Filings8(57%)
- Market4(29%)
- Other1(7%)
- Insider1(7%)
Latest news
25 items- NEWSCNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" SegmentAccess the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment.Steve O'Loughlin, Chief Financial Officer of CNS Pharmaceuticals, discussed the Company's recently completed oversubscribed $22.5 million financing in the virtual segment, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused transformation. The conversation explored investor reception to
- SECSEC Form EFFECT filed by CNS Pharmaceuticals Inc.EFFECT - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- SECSEC Form 424B3 filed by CNS Pharmaceuticals Inc.424B3 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- INSIDERDirector Charles Faith L. bought $34,002 worth of shares (7,100 units at $4.79) (SEC Form 4)4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- NEWSCNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation ProgressAccess the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor CEO Connect Segment.As part of the segment, Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value. Additionally, Mr. Levin d
- SECSEC Form D filed by CNS Pharmaceuticals Inc.D - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- SECSEC Form S-3 filed by CNS Pharmaceuticals Inc.S-3 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CNS Pharmaceuticals Inc.SCHEDULE 13G/A - CNS Pharmaceuticals, Inc. (0001729427) (Subject)
- NEWSCNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation ProgressOversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategyCompany actively evaluating multiple acquisition opportunities while advancing discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287New executive leadership team assembled in the first quarter continues to demonstrate rapid execution against strategy HOUSTON, TX / ACCESS Newswire / May 14, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline o
- SECSEC Form 10-Q filed by CNS Pharmaceuticals Inc.10-Q - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- SECCNS Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- NEWSCNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement FinancingThe private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare PartnersProceeds expected to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy HOUSTON, TX / ACCESS Newswire / May 4, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, announced today that it has entered into securities purchase agreements for a pr
- SECAmendment: SEC Form 10-K/A filed by CNS Pharmaceuticals Inc.10-K/A - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- SECSEC Form 10-K filed by CNS Pharmaceuticals Inc.10-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- SECCNS Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- NEWSCNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology PipelineNewly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing marketsStrategic transformation driven by a comprehensive data analysis will enable new executive team to leverage decades of experience in these therapeutic areasCompany pivoting from a singular focus on glioblastoma and will explore out-licensing of legacy assets berubicin and TPI 287HOUSTON, TX / ACCESS Newswire / March 11, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (the "Company"), a biotechnology company focused on building a pipeline of innovative therapies in high-value neurology and oncology markets, today
- INSIDERSEC Form 4 filed by Chief Technology Officer Faulkner Eric4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 3 filed by new insider Faulkner Eric3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer O'Loughlin Steve4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 3 filed by new insider O'Loughlin Steve3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- SECCNS Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- NEWSCNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership TeamDr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNSNewly formed executive team is committed to execution and company evolution focused on patient and stakeholder valueHOUSTON, TX / ACCESS Newswire / March 2, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer.Dr. Kelley brings more than two decades of global leadership experience across clinical dev
- SECSEC Form S-8 filed by CNS Pharmaceuticals Inc.S-8 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- SECCNS Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- NEWSCNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic TransformationNew Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value CreationHOUSTON, TX / ACCESS Newswire / February 17, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the Company's recently appointed President and Chief Executive officer, Rami Levin, in close alignment with the Board of Directors, has recruited key members to his new executive team. These new appointments, which will be effecti
CNSP FAQ
6 questionsWhat does CNS Pharmaceuticals Inc. do?
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.Where does CNSP stock trade?
CNS Pharmaceuticals Inc. (CNSP) is listed on NASDAQ.What sector and industry is CNSP in?
CNS Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did CNS Pharmaceuticals Inc. go public?
CNS Pharmaceuticals Inc. (CNSP) completed its IPO in 2019.What companies are similar to CNSP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CNSP side-by-side with any of them on Quantisnow.How can I track CNSP on Quantisnow?
Quantisnow aggregates CNS Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CNSP to receive live email and push alerts on every new disclosure.